Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 1
2000 2
2002 2
2003 9
2004 6
2005 3
2006 3
2007 6
2008 3
2009 1
2010 2
2011 5
2012 5
2013 10
2014 10
2015 10
2016 7
2017 6
2018 1
2019 2
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24925537

90 results

Results by year

Filters applied: . Clear all
Page 1
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators. Bonaventura A, et al. Int J Gynecol Cancer. 2017 Jun;27(5):900-906. doi: 10.1097/IGC.0000000000000978. Int J Gynecol Cancer. 2017. PMID: 28498256 Clinical Trial.
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Tang M, O'Connell RL, Amant F, Beale P, McNally O, Sjoquist KM, Grant P, Davis A, Sykes P, Mileshkin L, Moujaber T, Kennedy CJ, deFazio A, Tan K, Antill Y, Goh J, Bonaventura T, Scurry J, Friedlander M. Tang M, et al. Gynecol Oncol. 2019 Sep;154(3):531-538. doi: 10.1016/j.ygyno.2019.06.011. Epub 2019 Jun 18. Gynecol Oncol. 2019. PMID: 31227223 Clinical Trial.
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
Kok PS, Beale P, O'Connell RL, Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, DeFazio A, Mapagu C, Amant F, Friedlander M; PARAGON Investigators. Kok PS, et al. J Gynecol Oncol. 2019 Sep;30(5):e86. doi: 10.3802/jgo.2019.30.e86. J Gynecol Oncol. 2019. PMID: 31328463 Free PMC article. Clinical Trial.
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial.
Banerjee SN, Tang M, O'Connell RL, Sjoquist K, Clamp AR, Millan D, Nottley S, Lord R, Mullassery VM, Hall M, Gourley C, Bonaventura T, Goh JC, Sykes P, Grant PT, McNally O, Alexander L, Kelly C, Carty K, Divers L, Bradshaw N, Edmondson RJ, Friedlander M; PARAGON investigators. Banerjee SN, et al. Gynecol Oncol. 2021 Oct;163(1):72-78. doi: 10.1016/j.ygyno.2021.07.024. Epub 2021 Aug 16. Gynecol Oncol. 2021. PMID: 34412908 Clinical Trial.
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Aihara T, Yokota I, Hozumi Y, Aogi K, Iwata H, Tamura M, Fukuuchi A, Makino H, Kim R, Andoh M, Tsugawa K, Ohno S, Yamaguchi T, Ohashi Y, Watanabe T, Takatsuka Y, Mukai H. Aihara T, et al. Breast Cancer Res Treat. 2014 Nov;148(2):337-43. doi: 10.1007/s10549-014-3155-8. Epub 2014 Oct 16. Breast Cancer Res Treat. 2014. PMID: 25318924 Clinical Trial.
90 results